neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig
Company profile
Ticker
NEO
Exchange
Website
CEO
Douglas M. Van Oort
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMERICAN COMMUNICATIONS ENTERPRISES INC
SEC CIK
Corporate docs
Subsidiaries
Clarient Diagnostic Services, Inc. • Clarient, Inc. • Cynogen, Inc. • Genesis Acquisition Holdings Corp. • Genoptix, Inc. • Inivata Limited • Inivata, Inc. • Minuet Diagnostics, Inc. • NeoGenomics Bioinformatics, Inc. • NeoGenomics Europe, SA ...
IRS number
742897368
NEO stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
18 Apr 24
ARS
2023 FY
Annual report to shareholders
8 Apr 24
DEFA14A
Additional proxy soliciting materials
8 Apr 24
DEF 14A
Definitive proxy
8 Apr 24
8-K/A
Departure of Directors or Certain Officers
26 Feb 24
8-K
Departure of Directors or Certain Officers
23 Feb 24
10-K
2023 FY
Annual report
20 Feb 24
8-K
NeoGenomics Reports Fourth Quarter and Full Year 2023 Results
20 Feb 24
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
NeoGenomics Reports Third Quarter 2023 Results
6 Nov 23
Transcripts
NEO
Earnings call transcript
2023 Q4
20 Feb 24
NEO
Earnings call transcript
2023 Q3
6 Nov 23
NEO
Earnings call transcript
2023 Q2
8 Aug 23
NEO
Earnings call transcript
2023 Q1
8 May 23
NEO
Earnings call transcript
2022 Q4
23 Feb 23
NEO
Earnings call transcript
2022 Q3
8 Nov 22
NEO
Earnings call transcript
2022 Q2
9 Aug 22
NEO
Earnings call transcript
2022 Q1
27 Apr 22
NEO
Earnings call transcript
2021 Q4
23 Feb 22
NEO
Earnings call transcript
2021 Q3
4 Nov 21
Latest ownership filings
4
LYNN A. TETRAULT
6 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
4
Warren Stone
27 Feb 24
4
Alicia C Olivo
27 Feb 24
4
Jeffrey Scott Sherman
27 Feb 24
4
Christopher M Smith
27 Feb 24
4
Melody Harris
27 Feb 24
4
Vishal Sikri
27 Feb 24
4
Alicia C Olivo
20 Feb 24
144
Notice of proposed sale of securities
15 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 306.24 mm | 306.24 mm | 306.24 mm | 306.24 mm | 306.24 mm | 306.24 mm |
Cash burn (monthly) | (no burn) | (no burn) | 8.07 mm | 9.63 mm | 1.83 mm | 1.95 mm |
Cash used (since last report) | n/a | n/a | 54.97 mm | 65.62 mm | 12.49 mm | 13.30 mm |
Cash remaining | n/a | n/a | 251.27 mm | 240.62 mm | 293.75 mm | 292.94 mm |
Runway (months of cash) | n/a | n/a | 31.2 | 25.0 | 160.3 | 150.1 |
Institutional ownership, Q3 2023
93.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 277 |
Opened positions | 41 |
Closed positions | 25 |
Increased positions | 73 |
Reduced positions | 100 |
13F shares | Current |
---|---|
Total value | 1.47 tn |
Total shares | 119.32 mm |
Total puts | 204.40 k |
Total calls | 629.60 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 20.10 mm | $247.27 bn |
Vanguard | 14.32 mm | $176.09 bn |
Brown Advisory | 8.25 mm | $101.43 bn |
JHG Janus Henderson | 7.17 mm | $88.25 bn |
T. Rowe Price Investment Management | 5.53 mm | $67.85 bn |
STT State Street | 4.92 mm | $60.57 bn |
Greenhouse Funds LLLP | 3.98 mm | $48.97 bn |
First Light Asset Management | 3.03 mm | $37.26 bn |
MCQEF Macquarie | 3.02 mm | $37.13 bn |
Dimensional Fund Advisors | 2.99 mm | $36.75 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Feb 24 | Warren Stone | Performance Stock Unit Common Stock | Grant | Acquire A | No | No | 0 | 25,330 | 0.00 | 25,330 |
23 Feb 24 | Warren Stone | RSU Common Stock | Grant | Acquire A | No | No | 0 | 25,329 | 0.00 | 25,329 |
23 Feb 24 | Warren Stone | Stock Option Common Stock | Grant | Acquire A | No | No | 16.45 | 42,344 | 696.56 k | 42,344 |
23 Feb 24 | Alicia C Olivo | Performance Stock Unit Common Stock | Grant | Acquire A | No | No | 0 | 25,330 | 0.00 | 25,330 |
23 Feb 24 | Alicia C Olivo | RSU Common Stock | Grant | Acquire A | No | No | 0 | 25,329 | 0.00 | 25,329 |
23 Feb 24 | Alicia C Olivo | Stock Option Common Stock | Grant | Acquire A | No | No | 16.45 | 42,344 | 696.56 k | 42,344 |
23 Feb 24 | Jeffrey Scott Sherman | Performance Stock Unit Common Stock | Grant | Acquire A | No | No | 0 | 46,606 | 0.00 | 46,606 |
23 Feb 24 | Jeffrey Scott Sherman | RSU Common Stock | Grant | Acquire A | No | No | 0 | 46,606 | 0.00 | 46,606 |
23 Feb 24 | Jeffrey Scott Sherman | Stock Option Common Stock | Grant | Acquire A | No | No | 16.45 | 77,913 | 1.28 mm | 77,913 |
23 Feb 24 | Christopher M Smith | Performance Stock Unit Common Stock | Grant | Acquire A | No | No | 0 | 172,240 | 0.00 | 172,240 |
News
Ethereum Surpasses $3,000; Akash Network Emerges As Top Gainer
17 Apr 24
Bitcoin Falls Below $63,000; Nervos Network, AIOZ Network Among Top Losers
16 Apr 24
Bitcoin Surpasses $66,000; Core Emerges As Top Gainer
15 Apr 24
Bitcoin Surpasses $70,000 Following PPI Data; JasmyCoin Emerges As Top Gainer
11 Apr 24
Bitcoin Falls Below $71,000 Data; Wormhole, Core Among Top Losers
9 Apr 24
Press releases
NeoGenomics Announces Senior Leadership Promotions
18 Apr 24
NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024
9 Apr 24
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
27 Mar 24
NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference
1 Mar 24
NeoGenomics Signs Working with Cancer Pledge in Support of Employees
1 Feb 24